Clinical Trial Update: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP 501 to Adalimumab in adults with moderate to severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ABP 501 (adalimumab biosimilar)
• Humira (adalimumab)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2016-12-13